Abstract: A method for treating a subject having a cutaneous thermal injury is disclosed. The method comprises administering a therapeutically effective amount of a bactericidal compound topically to the injury. Use of a therapeutically effective amount of a bactericidal compound topically for treating a subject having a cutaneous thermal injury is also disclosed. The bactericidal compound comprises a therapeutically effective amount of NaNO2 (A-NO2—) and di-sodium EDTA (Na2-EDTA).

Abstract: Suspensions and their use for treating tumors are provided, where the suspensions include (a) particles of at least 95% by weight of cisplatin, wherein the particles have a specific surface area (SSA) of at least 3.5 m2/g, (b) about 40% to about 60% w/w of glycerin, (c) about 20% to about 40% w/w of propylene glycol, (d) about 5% to about 20% w/w of ethanol, and (e) about 5% to about 10% w/w of 0.9% sodium chloride in water.

Abstract: Disclosed are compositions of matter, protocols, and treatment means for prevention and/or reversing Chronic Obstructive Pulmonary Disease (COPD) using myeloid derived suppressor cells as a monotherapy or adjuvant therapy. In one embodiment umbilical cord low density myeloid cells are expanded using interleukin-3 and GM-CSF and administered in an allogeneic manner to a mammal suffering from COPD. In some embodiments combinations of myeloid derived suppressor cells and mesenchymal stem cells are disclosed.

Abstract: The present invention relates to therapeutic compositions and methods for sequential treatment of cancer in human patients using therapeutic agents that bind to human CD1g.

Abstract: The present invention provides chimeric antigen receptors (CAR) and methods of use in the treatment of diseases and disorders.

Abstract: A target protein for viral vector-based anticancer therapy, and a binding molecule or a fragment thereof which specifically binds thereto are disclosed. A conformational epitope of protein A56, and a binding molecule or a fragment thereof which specifically binds thereto are disclosed. The A56-binding molecule or a fragment thereof, which binds to a conformational epitope of A56 forms a specific structural bond with A56 and shows high affinity thereto. Administering a vaccinia virus-based oncolytic virus, A56 is expressed on the cancer cell surface in various carcinomas. The A56-binding molecule or a fragment thereof effectively targets A56 that is specifically expressed on the cancer cell surface, which enables targeted therapy for cancer cells that have survived even infection with an oncolytic virus, thereby providing effective anticancer therapy.

Abstract: Provided herein are multi-functional chimeric antigen receptor (CAR)-based compositions and their use in directing immune responses to target cells. The compositions have uses that include treating hyperproliferative disorders such as cancer. The provided methods generally include the use of a CAR cell in combination with an Adapter. The Adapter confers the ability to modulate, alter, and/or redirect CAR cell-mediated immune response in vitro and in vivo. In some embodiments, the CAR cell comprises a genetic modification to reduce or eliminate the expression of a targeted antigenic determinant.

Abstract: This disclosure describes chimeric antigen receptors (CARs) engineered immune cells including the CARs, pharmaceutical compositions that include engineered immune cells that include the CARs, and methods involving such engineered immune cells.

Abstract: The present invention provides recombinant TIM-4 fusion proteins comprising a domain of TIM-4 and a scFv specific for CD3 and methods of making and using the same. The fusion proteins provided herein may be administered in combination with CAR T cells. In addition CAR T cells engineered to express the TIM-4 fusion proteins described herein are also provided and may be used in the methods described herein.

Abstract: The present invention provides methods for increasing the sensitivity of tumor cells to a TCR-engineered T cells (TCR-T) therapy comprising genetically modifying the tumor cells to express an haplotype, for example an HLA haplotype, different from the haplotype endogenous to the tumor cells.

Abstract: Herein are provided anti-EGFR single domain antibodies (sdAb) prepared by immunizing a llama with recombinant human EGFRvIII. VHH antibodies specific to EGFR were isolated. The example antibodies initially produced comprise CDR1, CDR2, and CDR3 sequences corresponding, respectively to SEQ NOs: 1-3, 4-6, 7-9, 10-12, 13-15, 16-18, 19-21, 22-24, 25-27, 28-30, 31-33, 34-36, 37-39, 40-42, 43-45, and 46-48; and related sequences, including humanized variants. Also provided are multivalent antibodies comprising any one of the sdAbs, including bispecific T-cell engagers, bispecific killer cell engagers (BiKEs), and trispecific killer cell engagers (TriKEs). Also described are chimeric antigen receptors (CARs) for CAR-T therapy comprising any one of the aforementioned sdAbs. Uses of these molecules in the treatment of cancer are also described, in particularly EGFR-high cancers. Hinge lengths may be selected to achieve desired activities, such as high activity or high selectivity for target vs. non-target cells.

Abstract: The present invention relates to cytokine induced Killer cells (CIKs) for use in the treatment of diseases caused by a Plasmodium infection.

Abstract: The present disclosure provides methods of treating disease and disorders of the hematological system. The disclosure provides a method of expanding a population of hematopoietic stem cells (HSCs) while maintaining the population in an undifferentiated state comprising contacting the population of HSCs in the presence of a CMA activator for a period of time until a sufficient number of HSCs is obtained thereby producing an expanded HSC population.

Abstract: Provided herein are compositions, methods, and systems, comprising a programmable nucleic acid-guided nuclease and donor polynucleotides sequences to introduce an exogenous polynucleotide sequence, which encodes a therapeutic protein linked to a transmembrane domain. The composition of the disclosure is introduced into a cell, such as an HSPC, wherein the HSPC can be further differentiated.

Abstract: Disclosed herein are methods for generating SC-? cells, and isolated populations of SC-? cells for use in various applications, such as cell therapy.

Abstract: Equine-specific therapeutic compositions comprising placental-derived materials and methods of use, and method of producing said equine-specific therapeutic compositions that is clear, safe, and physiologically and biologically active liquid injectable. The tissue processing protocols described herein include methods for processing and decontaminating the incoming placental tissue and fluid having coloration and contaminants to produce a clear amnion and amniotic fluid injectable product while preserving postbiotics, proteins, exosomes, biocomponents and maintaining their physiological and biological properties.

Abstract: The present invention relates to compositions comprising phospholipids for delivery of bioactive compounds such as ethyl esters, fish oil concentrates, cannabinoids, and curcumin under conditions such the bioavailability of the bioactive compounds is enhanced.

Abstract: Compositions include honey or a honey analog, gluconic acid or a pharmaceutically acceptable salt or derivative thereof, and a pharmaceutically acceptable carrier. The compositions can be used for treating or inhibiting the development of an infection or an inflammatory condition or for treating a wound. Gluconic acid or a pharmaceutically acceptable salt or derivative thereof can stabilize the pH of a composition that includes honey or a honey analog.

Abstract: Compositions, systems and methods of improving the health of the microbiome of an individual's skin relate to the provision of skin contacting formulations containing beneficial bacteria and other microbe components to foster the growth and maintenance of a healthy skin microbiome. Embodiments include methods for treating an individual suffering from acne valgaris by topically administering a composition that includes live bacteria selected from the group consisting of L reuteri, L johnsonii, L crispatus, C. acnes, and Nitrosomonas eutropha, that have been modified by using a using a clustered regularly interspaced short palindromic repeats (CRISPR) CRISPR associated protein (Cas) system or a CRISPR from Prevotella and Francisella 1 (Cpf1) system to reduce the production of a virulence factor of the bacteria.

Abstract: The present invention relates to a composition which contains an intestinal bacterium belonging to the genus Veillonella and having an inflammation reducing activity, or a substance derived from the intestinal bacterium and having an inflammation reducing activity and which has at least one activity selected from an anti-inflammatory activity, an immunoregulation activity, an epithelial barrier restoring activity, an IL-10-inducing activity, and an IL-22-inducing activity, and to an ameliorating agent for an inflammatory disease, an autoimmune disease, or an infectious disease containing the intestinal bacterium and the substance derived from the intestinal bacterium and having an inflammation reducing activity.

Abstract: The invention relates to therapeutic compositions comprising at least one isolated bacterium and a pharmaceutically acceptable excipient, as well as methods of preparing such therapeutic compositions. The therapeutic compositions find application in the treatment of dysbiosis, in particular dysbiosis of the gastrointestinal tract.

Abstract: This disclosure relates to methods of using beneficial bacteria such as, a Lactococcus lactis strain, to manage, treat, or prevent obesity, fatty liver disease, harmful ionizing radiation, and other conditions or aliments. In certain embodiments, the subject is at risk or, susceptible to, exhibiting symptoms of, or diagnosed with a disease or conditions disclosed herein. In certain embodiments, methods comprise administering an effective amount of a Lactococcus lactis strain to a subject in need thereof. In certain embodiments, the Lactococcus lactis strain is Lactococcus lactis subsp. cremoris ATCC® 19257 or a mutant thereof.

Abstract: The current invention concerns preparations comprising at least one probiotic strain belonging to the species Lactobacillus helveticus, Lactobacillus rhamnosus (Lacticaseibacillus rhamnosus), Lactobacillus mucosae (Limosilactobacillus mucosae), and Lactobacillus johnsonii and anthocyanins.

Abstract: The present invention relates to an oral composition for animal, containing mastic resin and/or mastic essential oil as active components, especially a valid oral composition for pet animals, such as dogs and cats. An oral composition for animal, for sterilizing a periodontal disease bacterium and an infection disease bacterium, characterized in that, said oral composition contains mastic resin as an active component, and said periodontal disease bacterium is Porphyromonas circumdentaria.

Abstract: The present invention provides a mitochondrial function-improving agent containing a lactic acid bacterium belonging to Lactobacillus farciminis or Pediococcus acidilactici, a culture of the lactic acid bacterium, or a culture supernatant of the lactic acid bacterium.

Abstract: The invention relates to a pharmaceutical composition for use in treating inflammation in the female genitourinary tract of a human subject, wherein the female subject exhibits a dysbiotic microbiota in the genitourinary tract. The pharmaceutical composition comprises a substantially complete vaginal microbiota preparation, wherein the preparation (i) comprises one, two, three or four bacterial species from the genus Lactobacillus, selected from Lactobacillus crispatus, Lactobacillus iners, Lactobacillus jensenii, Lactobacillus gasseri, which comprise about 80-99.9% of all detectable bacterial species of the preparation; and (ii) comprises less than 5% of Gardnerella spp., Atopobium spp., and Prevotella spp.; wherein the pharmaceutical composition comprises a pharmaceutically acceptable carrier or diluent. The invention further relates to a method of preparing said composition, and devices comprising and/or using the same.

Abstract: The invention herein relates generally to enhancing the survival and activity of probiotic Lactobacillus strains in mammals. Lactobacillus strain comprising a LacS transporter sequence having a sequence identity of at least 70% to SEQ ID NO: 1, and/or comprising a GH42 B-gal sequence, wherein the Lactobacillus strain is not a Lactobacillus reuteri strain. The invention comprises methods for cultivating and manufacturing probiotic Lactobacillus strains, and products containing such strains. In more detail the GC present invention relates to a composition comprising probiotic Lactobacillus strains, obtained by a step of growing the bacteria in a medium comprising galacto-oligosaccharides (GOS) (“pre-conditioning”), and administering said pre-conditioned bacteria together with GOS in the final product. The inventors have found that such method induces a boost in the beneficial effects of the probiotic bacteria, such as survival in the gastrointestinal tract.

Abstract: Disclosed herein are compositions of nutraceuticals for use as dietary supplements and their use for supporting immunity, enhancing mood, improving well-being, improving cognitive function, providing adaptogenic support, providing antioxidant support, and suppressing appetite.

Abstract: One aspect of the present disclosure is to a skin external composition and a method for preparing the same, and more particularly, the skin external composition includes a Pueraria thunbergiana honey water extract as an active ingredient to exhibit excellent anti-inflammatory and moisturizing effects.

Abstract: The present disclosure relates a method for reducing animal weight, comprising administering to a patient in need thereof a therapeutically or prophylactically effective amount of a mulberry extract. The mulberry extract comprises: 3% to 99% of an alkaloid, 0.2% to 70% of a polysaccharide, 0% to 50% of an amino acid, 0% to 10% of flavone, and 0% to 25% of other components. The mulberry extract of the present disclosure can be used for controlling weight gain, and has a good therapeutic effect on type 2 diabetes with obesity.

Abstract: A composition containing Gardenia jasminoides-derived exosomes as an active ingredient is provided for skin elasticity improvement, skin wrinkle reduction, skin regeneration, skin tone improvement, skin brightness improvement, skin whitening, wound healing and/or wound healing acceleration.

Abstract: The present invention relates to an extract of Salvia miltiorrhiza and/or an extract of Poncirus trifoliata for inhibiting obesity. In particular, the extract of Salvia miltiorrhiza and/or the extract of Poncirus trifoliata is/are prepared by solvent or supercritical fluid extraction. Specifically, the extract of Salvia miltiorrhiza and/or the extract of Poncirus trifoliata is/are effective in inhibiting lipid accumulation in adipocytes and slowing down body weight gain of the subject. More specifically, the extract of Salvia miltiorrhiza and/or the extract of Poncirus trifoliata can be used in combination with an extract of Curcuma longa, which exhibit improved effects in inhibiting lipid accumulation in adipocytes and slowing down body weight gain of the subject.

Abstract: The disclosure provides methods of preventing or treating Barth Syndrome in a mammalian subject, reducing risk factors associated with Barth Syndrome, and/or reducing the likelihood or severity of Barth Syndrome. The methods comprise administering to the subject an effective amount of an aromatic-cationic peptide to increase expression of TAZ1 in subjects in need thereof.

Abstract: The present invention provides a compound for use in the treatment of an enveloped virus infection in a subject, wherein said compound is a compound of Formula (I) as defined herein: AA-AA-AA-X-Y-Z (I). The invention further provides a method of treating an enveloped virus infection in a subject, which method comprises administering to a subject in need thereof an effective amount of a compound of Formula (I).

Abstract: The present invention provides a conjugate and preparation method thereof, a pharmaceutical composition comprising the conjugate and use of the pharmaceutical composition in the manufacture of a medicament for the treatment or prevention of a disease.

Abstract: The principles and embodiments of the present disclosure relate to a composition for improving kidney function in an adult patient with hepatorenal syndrome with rapid reduction in kidney function. The composition includes terlipressin acetate having a formula of C52H74N16O15S2·(C2H4O2)n, where n is 2.8.

Abstract: The present invention provides polypeptide modulators of complement activity, including cyclic polypeptide modulators. Also provided are methods of utilizing such modulators as therapeutics.

Abstract: Provided are novel peptides, methods of their preparation and their use in controlled release of pharmaceutically active compounds.

Abstract: Provided herein are methods and compositions for treating ocular diseases, disorders, and conditions. Described are compositions and methods for preventing, treating, or ameliorating an inflammation-mediated disease or condition in an individual comprising administering to the subject a Fas inhibitor, its derivative, or a pharmaceutically acceptable salt thereof.

Abstract: Antimicrobial peptides, compositions and methods are described that are useful for treating infectious disease, including those caused by drug resistant Gram-negative bacteria (e.g., Pseudomonas and Acinetobacter) and parasite-caused disease such as malaria. The peptides include a modular kinocidin gamma-core connected directly, or through a short spacer, to a kinocidin C-terminal alpha-helix.

Abstract: The present disclosure generally relates to systems and methods for delivering humanin and/or other peptides to a subject. In some cases, these may be used for treating or preventing aging skin, or for other diseases. Non-limiting examples of other peptides include mitochondrial-derived peptides such as HNG or MOTS-c. In addition, certain embodiments are generally directed to treatments that can be delivered using topical compositions applied to the skin. For example, in some cases, the composition includes lecithin and/or other components that may facilitate delivery through the skin. Further, certain embodiments may include active ingredients such as tributyrin or 2,6-dimethyl-L-tyrosine, which may interact with humanin or other peptides. Compositions such as these may be used in certain embodiments, for example, to reduce inflammation within the skin, or as an anti-aging treatment, etc.

Abstract: Disclosed herein are compositions and methods for treating cancers. Also disclosed herein are methods for detecting subjects' responsiveness to immunotherapy and for reversing resistance to immunotherapy.

Abstract: The present disclosure generally relates to pharmaceutical compositions useful for the treatment of diseases and disorders. More particularly, the disclosure relates to pharmaceutical compositions comprising peptides that selectively inhibit NF-?B activation control or inhibit alpha(?)-synucleinopathy and neuronal loss in neurodegenerative diseases in which ?-synuclein and/or NF-?B play a role in disease pathogenesis. The pharmaceutical compositions useful for the invention are preferably administered intranasally.

Abstract: The present invention relates to oral composition and the method of preparation and use of such composition for inhibiting, reducing, and/or disrupting oral biofilm. The composition comprises a stabilizing matrix, a cationic biocide, and a peroxide source.

Abstract: An application of insulin-like growth factor-binding protein 2 (IGFBP2) in the preparation of drugs for resisting mental disorders caused by early-life stress. IGFBP2 puberty intervention and adult intervention can significantly improve anxiety and depression behaviors caused by early life stress.

Abstract: Fas-associated factor 1 (FAF1) protein-loaded exosomes and a cancer treatment using FAF1 protein-loaded exosomes are disclosed. FAF1 protein-loaded exosomes are isolated from HEK 293 cells in which FAF1 having a known tumor-suppressive function is overexpressed and administered the FAF1 protein-loaded exosomes to various tumor models in which pancreatic cancer cells (MIA PaCa-2), lung cancer cells (A549), colon cancer cells (HCT 116), liver cancer cells (Hep3B), breast cancer cells (MDA-MB-231), kidney cancer cells (Caki-1) and cervical cancer cell (HeLa cell) are transplanted into nude mice through intratumoral injection. The administration exhibited tumor growth inhibitory effects remarkably greater than those of a control group not treated with FAF1.

Abstract: Disclosed is an Ixodes ricinus salivary gland polypeptide and its use for inhibiting the extrinsic coagulation pathway and for treating and/or preventing diseases and conditions, such as thrombotic events, associated with the recruitment and activation of neutrophils following activation of the extrinsic coagulation pathway.

Abstract: The present invention relates to novel liquid formulations comprising pharmacologically active fusion protein. The present invention discloses the use of histidine buffer in combination with other excipients to stabilize the fusion protein by lowering the product related impurities. In another aspects invention provides a formulation of fusion protein with low viscosity.

Abstract: Disclosed herein are methods using sEphB4-HSA an effective first-line therapy for cancers where current therapies are ineffective, result in relapse, or are not even considered for use due to the type of cancer and related tumors.

Abstract: The present invention relates to compositions comprising resolvins and their use in methods of treating cancer.